Novo Nordisk announces Health Canada has granted priority review status for once-weekly semaglutide to treat metabolic dysfunction-associated steatohepatitis.
Recommendations also provided for hormone replacement therapy following preventive hysterectomy/bilateral salpingo-oophorectomy and daily ASA to prevent colon cancer.